Presentation is loading. Please wait.

Presentation is loading. Please wait.

Distinct Clinical Course of EGFR-Mutant Resected Lung Cancers: Results of Testing of 1118 Surgical Specimens and Effects of Adjuvant Gefitinib and Erlotinib 

Published byYanti Ratna Pranata Modified over 6 years ago

Similar presentations

Presentation on theme: "Distinct Clinical Course of EGFR-Mutant Resected Lung Cancers: Results of Testing of 1118 Surgical Specimens and Effects of Adjuvant Gefitinib and Erlotinib "— Presentation transcript:

1 Distinct Clinical Course of EGFR-Mutant Resected Lung Cancers: Results of Testing of Surgical Specimens and Effects of Adjuvant Gefitinib and Erlotinib  Sandra P. D’Angelo, MD, Yelena Y. Janjigian, MD, Nicholas Ahye, BA, Gregory J. Riely, MD, PhD, Jamie E. Chaft, MD, Camelia S. Sima, MD, MS, Ronglai Shen, PhD, Junting Zheng, MS, Joseph Dycoco, BA, Mark G. Kris, MD, Maureen F. Zakowski, MD, Marc Ladanyi, MD, Valerie Rusch, MD, Christopher G. Azzoli, MD  Journal of Thoracic Oncology  Volume 7, Issue 12, Pages (December 2012) DOI: /JTO.0b013e31826bb7b2 Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 OS comparing patients with EGFR-mutant versus EGFR wild-type tumors. OS, overall survival; CI, confidence interval; NA, not available. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e31826bb7b2) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 OS comparing patients with KRAS-mutant versus KRAS wild-type tumors. OS, overall survival, CI, confidence interval; NA, not available. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e31826bb7b2) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 DFS in patients with EGFR-mutant lung cancer with (TKI) and without (no TKI) adjuvant gefitinib or erlotinib. DFS, disease-free survival; TKI, tyrosine kinase inhibitors; HR, hazard ratio. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e31826bb7b2) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

5 FIGURE 4 OS in patients with EGFR-mutant lung cancer with (TKI) and without (no TKI) adjuvant gefitinib or erlotinib. OS, overall survival, TKI, tyrosine kinase inhibitors; HR, hazard ratio. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e31826bb7b2) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Distinct Clinical Course of EGFR-Mutant Resected Lung Cancers: Results of Testing of 1118 Surgical Specimens and Effects of Adjuvant Gefitinib and Erlotinib "

Similar presentations

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.
Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma  Zoltan Lohinai, MD, Mir Alireza Hoda, MD,

Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma  Zoltan Lohinai, MD, Mir Alireza Hoda, MD,
Jarrod D. Predina, BA, Matthew M. Puc, MD, Meredith R

Jarrod D. Predina, BA, Matthew M. Puc, MD, Meredith R
EGFR Mutations in Lung Adenocarcinomas

EGFR Mutations in Lung Adenocarcinomas
Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma  Kazuya Takamochi, MD, Shiaki Oh, MD,

Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma  Kazuya Takamochi, MD, Shiaki Oh, MD,
Prognostic Factors in the Treatment of Malignant Pleural Mesothelioma at a Large Tertiary Referral Center  Raja M. Flores, MD, Maureen Zakowski, MD, Ennapadam.

Prognostic Factors in the Treatment of Malignant Pleural Mesothelioma at a Large Tertiary Referral Center  Raja M. Flores, MD, Maureen Zakowski, MD, Ennapadam.
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.
Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,
Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.
Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer: An Analysis of Patients from.

Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer: An Analysis of Patients from.
Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,
Chee Khoon Lee, PhD, Johnathan Man, M. B. B. S

Chee Khoon Lee, PhD, Johnathan Man, M. B. B. S
Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations

Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations
A Randomized, Placebo-Controlled, Multicenter, Biomarker-Selected, Phase 2 Study of Apricoxib in Combination with Erlotinib in Patients with Advanced.

A Randomized, Placebo-Controlled, Multicenter, Biomarker-Selected, Phase 2 Study of Apricoxib in Combination with Erlotinib in Patients with Advanced.
Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas  Yiliang Zhang, MD, Rui Wang, MD, PhD, Yuan.

Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas  Yiliang Zhang, MD, Rui Wang, MD, PhD, Yuan.
Nicolas Girard, MD, Julie Teruya-Feldstein, MD, Eden C

Nicolas Girard, MD, Julie Teruya-Feldstein, MD, Eden C
Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.

Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.
Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non–Small Cell Lung Cancer Treated.

Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non–Small Cell Lung Cancer Treated.
Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With.

Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With.
Gemcitabine and Irinotecan for Patients with Untreated Extensive Stage Small Cell Lung Cancer: SWOG 0119  Wallace Akerley, MD, Jason McCoy, MS, Paul J.

Gemcitabine and Irinotecan for Patients with Untreated Extensive Stage Small Cell Lung Cancer: SWOG 0119  Wallace Akerley, MD, Jason McCoy, MS, Paul J.

Similar presentations

Ads by Google